REDWOOD CITY, Calif., June 5 /PRNewswire-FirstCall/ -- Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the Goldman Sachs 28th Annual Global Healthcare Conference in Dana Point, California, on Tuesday, June 12, 2007 at 2:40 p.m. Pacific Time (5:40 p.m. Eastern Time). Stuart Pollard, Maxygen’s chief scientific officer, will present. A live webcast of the presentation can be accessed on Maxygen’s website at http://www.maxygen.com/webcasts. The webcast will be archived for 30 days.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Products developed by Maxygen now in clinical trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia. Maxygen’s approach may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com
Maxygen, Inc.
CONTACT: Michele Boudreau, Investor and Public Relations of Maxygen, Inc.+1-650-279-2088
Web site: http://www.maxygen.com/
